Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
NASDAQ:UNCY
Unicycive Therapeutics, Inc. (UNCY) dilution facts from SEC filings
Snapshot as of Sep 30, 2026, built from 39 SEC filings.
- Warrants outstanding
- 3 warrant series recorded as outstanding
- Most recent offering
- None recorded in the filings reviewed
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.